🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

HCC treatment guideline statements from EASLnews presented by Bruno Sangro • Neoadjuvant/adjuvant IO not recommended • Combo LRT + systemic not recommended • Bland embo alternative to TACE • Y90 or SBRT alternative to ablation • SBRT alternative to TACE #EASLCongress

Great points 📍

Presentazione del progetto "Love Your Liver" alla cerimonia di apertura del convegno annuale dell’EASL (European Association of the Study of the Liver) - Milano, 5 giugno 2024 unipa.it/dipartimenti/p… #LoveYourLiver #EASL #LiverHealth #AISF #UniversityofPalermo #PROMISE

🔥hot of the press: the new Impact Factors🔥 👉the TOP journals in Gastroenterology & Hepatology ESMO - Eur. Oncology EASLnews ILCA #livertwitter

Navigating the landscape of liver cancer management ➡️Study designs in clinical trials and clinical practice #OpenAccess here👉bit.ly/3xfqPtQ Giuseppe Cabibbo Ciro Celsa Lorenza Rimassa JordiRimola Jordi Bruix Maria Reig #LiverTwitter

Liver decompensation 🧨 is the major driver of mortality in immunotherapy recipients with #HCC - with Ciro Celsa Giuseppe Cabibbo we highlight how this is etiology driven with 📈 higher decompensation rates in non-viral HCC Surgery and Cancer UPO - Università journals.lww.com/hep/abstract/9…

⭕️Hepatic decompensation and mortality in HCC treated with atezo-beva HEPATOLOGY Journal 🚨Decompensation and disease progression are independent prognostic factors ➡️Decompensation HR: 19.04 (9.75-37.19) ➡️Progression HR: 9.91 (5.85-16.78) ✅Treatment of viral aetiology and

ORIGINAL ARTICLE Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment Celsa et al. ​​#LiverX tinyurl.com/549kxxae

Help this post hit 220K likes. The Kiffness deserves it.

October is going to finish, but commitment to #LiverCancerAwareness continues. Today, we hosted a conference on #HCC prevention and treatment, highlighting the establishment of our #Liver unit and our certified diagnostic-therapeutic pathway for #livercancer. Giuseppe Cabibbo

I strongly disagree the arrogant and undue interference in the politics of any sovereign state of the disgusting billionaire

1. prevention of decompensation plays a key role in keeping patients on treatment (disease modifying agents) 2. early detection keeps patients on treatment 3. DISSECT what is liver decompensation and what is NOT Sherrie Bhoori BCLC GROUP 2024 update Giuseppe Cabibbo David James Pinato 🇺🇦 Maria Reig

Studio coordinato dai professori Cabibbo e Cammà evidenzia il valore dell'immunoterapia contro l'epatocarcinoma unipa.it/dipartimenti/p… #promiseunipa #terzamissione #public_engagement #GiuseppeCabibbo #CalogeroCammà #atezolizumab #tumorealfegato #immunoterapia

Congratulations to Giuseppe Cabibbo on your public disclosure, “Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death.” doi.org/10.1158/1078-0… UniPa